Akero Therapeutics stockholders elect two Class III directors, ratify auditor, approve say-on-pay

Akero Therapeutics, Inc.

Judy Chou, Ph.D. elected as Class III director with 46.7M for, 15.4M withheld.
Tomas Heyman elected as Class III director, but received 34.0M withheld vs 28.0M for.
Ratification of Deloitte & Touche as auditor for FY2025 passed: 67.3M for, 38.6K against.
Non-binding advisory vote on executive compensation approved: 60.7M for, 1.2M against.
Annual meeting held June 3, 2025; 79.7M shares outstanding as of record date Apr 10.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.